Cumberland Pharmaceutical Inc. is a U.S. pharmaceutical company that announced the result about a drug Vibativ (telavancin), through online publication in Drugs-Real World Outcomes. The drug vibativ is used in clinical trials to treat multiple infections such as severe and complicated skin infection, joint and bone infections, endocarditis, bacteremia, and lower respiratory tract infections. The report was published in NASHVILLE, TENN on Nov 25, 2019.
The Cumberland Pharmaceutical company is working to provide a high-quality brand of medicines, trying to improve patient care. For hospital acute care a gastroenterology company acquires, develops and commercializes the brands. The company medical specialties are classified according to the expert prescribers that absorbed and reach the target site with appropriate concentrations.
FDA approved the drug for the treatment of numerous serious infections including bacterial, nosocomial infections, and bacterial pneumonia. Vibativ is used against the gram-positive bacterial pathogenic strains usually for the multi-resistant pathogen.
The Telavancin Observational Use Registry performed to collect the data for population characteristics, real-world clinical results prescription information about the treatment with vibativ in the patients having gram-positive infections. The data was taken from 45 U.S. websites that include 1063 patients based on the retrospective medical chart review. Out of 1063 patients, 945 show positive results against the infections when treated with the drug.
This includes 74% of patients with bacteremia, 80% with cSSSI, 79% with the joint and bone infection and 67% wit Lower respiratory tract infections. The finals results show the success real-world about the telavancin that is used by many clinicians for the treatment of various infections.
The discovery of this drug happened in a research program that is designed for the new antibiotics for treating severe infections against the staphylococcus aureus and gram-positive bacteria such as MRSA, MSSA. Vibativ is a drug that administers once in a day in the injection form a lipoglycopeptide antibiotic. It has intro application vitro and penetrates to the target site within six hours that performs the bactericidal activity in the body against the microbes.
This drug can be used in the U.S. to treat the adults against nosocomial infections, ventilator-associated bacterial pneumonia that causes by S. aureus in place of alternative treatments. It is also approved for treating the complicated skin and skin structure infections, bone and joint infections against the resistant strains of MRSA and susceptible strains of MSSA.
The efficacy of the drug against the gram-positive infections that are difficult to treat has been proven by a large number of multination registrational studies. These studies involve the largest group of cohort patients with infections. The comparison was made against the vancomycin in HABP/VABP. The drug was proved effective as it used in vitro and Vivo conditions to treat the infections at a broader level.